2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada-Reference-Cited by-同舟云学术

2020–2021 AMMI Canada guidance on the use of antiviral drugs for influenza in the setting of co-circulation of seasonal influenza and SARS-CoV-2 viruses in Canada

Published:2020-12 Issue:4 Volume:5 Page:214-222
ISSN:2371-0888
Container-title:Official Journal of the Association of Medical Microbiology and Infectious Disease Canada
language:en
Short-container-title:Official Journal of the Association of Medical Microbiology and Infectious Disease Canada

Author:

Mubareka Samira¹,Aoki Fred Y²,Allen Upton D³⁴⁵,Hatchette Todd F⁶⁷,Papenburg Jesse⁷⁸,Evans Gerald A⁹

Affiliation:

1. Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

2. Medical Microbiology and Pharmacology and Therapeutics, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

3. Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada

4. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

5. Division of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada

6. Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

7. Department of Pathology and Laboratory Medicine, Nova Scotia Health, Halifax, Nova Scotia, Canada

8. Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children’s Hospital, McGill University Health Centre, Montreal, Quebec, Canada

9. Division of Microbiology, Department of Clinical Laboratory Medicine, Optilab Montreal, McGill University Health Centre, Montreal, Quebec, Canada

Abstract

We provide an update to the Association of Medical Microbiology and Infectious Disease Canada foundation guidance for the upcoming 2020–2021 influenza season in Canada. Important issues for this year include the implications of co-circulation of SARS-CoV-2, the role of diagnostic testing, and a restatement of dosing and administration recommendations for neuraminidase inhibitors in various age groups and underlying health conditions. Although peramivir and baloxivir are now licensed in Canada, neither is currently marketed, so this guidance focuses on further optimizing the use of oseltamivir and zanamivir.

Publisher

University of Toronto Press Inc. (UTPress)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://jammi.utpjournals.press/doi/pdf/10.3138/jammi-2020-11-02

Reference28 articles.

1. 1.Australian Government, Department of Health. Australian influenza surveillance report and activity updates. https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-ozflu-flucurr.htm (Accessed September 17, 2020).

2. 2.World Health Organization. Global influenza surveillance and response system (GISRS). https://www.who.int/influenza/gisrs_laboratory/en/ (Accessed September 17, 2020).

3. 3.Wade, S. Record rates of flu vaccine uptake. https://www.premier.sa.gov.au/news/media-releases/news/record-rates-of-flu-vaccine-uptake (Accessed September 18, 2020).

4. Increased Risk of Noninfluenza Respiratory Virus Infections Associated With Receipt of Inactivated Influenza Vaccine

5. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials